Effect of G-CSF and GM-CSF on expression of TNF-alpha mRNA and CD69 and secretion of IgG in peripheral blood mononuclear cells from systemic lupus erythematosus patients.
- Author:
Chun LU
1
;
Juan LI
Author Information
1. Department of Dermatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China. luliyuan@163.net
- Publication Type:Journal Article
- MeSH:
Antigens, CD;
analysis;
Antigens, Differentiation, T-Lymphocyte;
analysis;
Dose-Response Relationship, Drug;
Granulocyte Colony-Stimulating Factor;
pharmacology;
Granulocyte-Macrophage Colony-Stimulating Factor;
pharmacology;
Humans;
Immunoglobulin G;
biosynthesis;
Lectins, C-Type;
Leukocytes, Mononuclear;
immunology;
Lupus Erythematosus, Systemic;
immunology;
RNA, Messenger;
analysis;
Tumor Necrosis Factor-alpha;
genetics
- From:
Journal of Experimental Hematology
2002;10(6):531-534
- CountryChina
- Language:Chinese
-
Abstract:
In order to understand the effect of hematopoietic stem cell mobilization agents, G-CSF and GM-CSF, on the expression of TNF-alpha mRAN and CD69 and secretion of IgG in SLE patients' peripheral blood mononuclear cells (PBMNC), expression of TNF-alpha mRNA and CD69 was measured by RT-PCR and flow cytometry, respectively, and IgG secretion by ELISA. The results showed that 0.1 - 2.0 microg/ml G-CSF did not affect the expression of TNF-alpha mRNA in active and static patients' PBMNC treated with 0.1 - 2.0 microg/ml cytokines, and 2.0 microg/ml GM-CSF increased the expression of TNF-alpha mRNA in active patients' PBMNC. G-CSF and GM-CSF did not interfere the expression of CD69 in active and static patients' PBMNC, however, the expression of CD69 was significantly increased in active patients' PBMNC treated with GM-CSF at more than 8 microg/ml. There was no obvious change of IgG secretion from PBMNC induced with 10 microg/ml G-CSF, while the IgG secretion was stimulated by 10 microg/ml GM-CSF. It was concluded that G-CSF as a mobilization agent could be safe to SLE patients, but GM-CSF may cause some harmful effects to patients because of the increase of the parameters relating to activity of lupus in active SLE patients.
